Cargando…

Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure

AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chirinos, Julio A., Sardana, Mayank, Oldland, Garrett, Ansari, Bilal, Lee, Jonathan, Hussain, Anila, Mustafa, Anique, Akers, Scott R., Wei, Wen, Lakatta, Edward G., Fedorova, Olga V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165935/
https://www.ncbi.nlm.nih.gov/pubmed/29969536
http://dx.doi.org/10.1002/ehf2.12319
_version_ 1783359936922648576
author Chirinos, Julio A.
Sardana, Mayank
Oldland, Garrett
Ansari, Bilal
Lee, Jonathan
Hussain, Anila
Mustafa, Anique
Akers, Scott R.
Wei, Wen
Lakatta, Edward G.
Fedorova, Olga V.
author_facet Chirinos, Julio A.
Sardana, Mayank
Oldland, Garrett
Ansari, Bilal
Lee, Jonathan
Hussain, Anila
Mustafa, Anique
Akers, Scott R.
Wei, Wen
Lakatta, Edward G.
Fedorova, Olga V.
author_sort Chirinos, Julio A.
collection PubMed
description AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme‐linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83–1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6–0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = −0.23; 95% CI = −0.42 to −0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09–0.43; P = 0.003) and with an increased risk of death or HF admissions during follow‐up (hazard ratio = 1.61; 95% CI = 1.13–2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess.
format Online
Article
Text
id pubmed-6165935
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61659352018-10-04 Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure Chirinos, Julio A. Sardana, Mayank Oldland, Garrett Ansari, Bilal Lee, Jonathan Hussain, Anila Mustafa, Anique Akers, Scott R. Wei, Wen Lakatta, Edward G. Fedorova, Olga V. ESC Heart Fail Original Research Articles AIMS: The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well‐known inhibitor of AVP secretion) in HF is unknown. METHODS AND RESULTS: We studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme‐linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83–1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6–0.77 pg/mL; P = 0.0002). Heart failure with preserved ejection fraction (but not HFrEF) was a significant predictor of higher AVP after adjustment for potential confounders. Arginine vasopressin levels were independently associated with a greater LA volume and also paradoxically, with lower ANP levels. Key independent correlates of higher AVP were the presence of HFpEF (standardized β = 0.32; 95% CI = 0.09–0.56; P = 0.0073) and the ANP/LA volume ratio (standardized β = −0.23; 95% CI = −0.42 to −0.04; P = 0.0196). Arginine vasopressin levels were independently associated with LV mass (β = 0.26; 95% CI = 0.09–0.43; P = 0.003) and with an increased risk of death or HF admissions during follow‐up (hazard ratio = 1.61; 95% CI = 1.13–2.29; P = 0.008). CONCLUSIONS: Arginine vasopressin is increased in HFpEF and is associated with LV hypertrophy and poor outcomes. Higher AVP is associated with the combination of LA enlargement and paradoxically low ANP levels. These findings may indicate that a relative deficiency of ANP (an inhibitor of AVP secretion) in the setting of chronically increased LA pressure may contribute to AVP excess. John Wiley and Sons Inc. 2018-07-03 /pmc/articles/PMC6165935/ /pubmed/29969536 http://dx.doi.org/10.1002/ehf2.12319 Text en Published 2018. This article is a U.S. Government work and is in the public domain in the USA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Chirinos, Julio A.
Sardana, Mayank
Oldland, Garrett
Ansari, Bilal
Lee, Jonathan
Hussain, Anila
Mustafa, Anique
Akers, Scott R.
Wei, Wen
Lakatta, Edward G.
Fedorova, Olga V.
Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title_full Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title_fullStr Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title_full_unstemmed Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title_short Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
title_sort association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165935/
https://www.ncbi.nlm.nih.gov/pubmed/29969536
http://dx.doi.org/10.1002/ehf2.12319
work_keys_str_mv AT chirinosjulioa associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT sardanamayank associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT oldlandgarrett associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT ansaribilal associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT leejonathan associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT hussainanila associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT mustafaanique associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT akersscottr associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT weiwen associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT lakattaedwardg associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure
AT fedorovaolgav associationofargininevasopressinwithlowatrialnatriureticpeptidelevelsleftventricularremodellingandoutcomesinadultswithandwithoutheartfailure